However, such a difference was not found in EGFR FISH-negative patients (P = 0.46).16 We used erlotinib in consideration of its radiosensitisation.17 The efficacy and tolerance of concurrent CRT and erlotinib in inoperable ESCC has been reported in a phase II study.18 The promising early results of the current study were previously reported.5 Chemoradiotherapy with ENI and erlotinib achieved significantly better overall survival and locoregional control than standard chemoradiotherapy in patients with locally advanced ESCC. Here, EGFR is linked to esophageal squamous cell carcinoma.